OvaScience to miss its goal of 1,000 AUGMENT treatment cycles this year; shares drop 33% premarket

• OvaScience (NASDAQ:OVAS-OLD) says it will come up short this year regarding its corporate goal of 1,000 AUGMENT treatment cycles. It cites its continuing efforts to enhance its commercial operations and infrastructure (in other words, "we not quite there yet") and evolving market dynamics in the fertility space, including recent M&A activities at key clinics which hindered the company's ability to drive volume.
• Goals for OvaPrime and OvaTure remain on track for 2015.
• Management will host a conference call this morning at 8:30 am ET to discuss their plans.
• Shares are off 33% premarket on average volume.